Top

Published in:

01-03-2012 | News item

Safety labelling changes for statins

Published in: Reactions Weekly | Issue 1/2012

Excerpt

On 28 February, the US FDA announced important safety changes to the labelling of statins regarding the associated risks of liver injury, cognitive disorders and hyperglycaemia.1 This announcement was followed by another drug safety communication from the FDA on 1 March, warning of drug interactions between statins and protease inhibitors, and the associated risks of myopathy.2 …

FDA.FDA announces safety changes in labeling for some cholesterol-lowering drugs. Media Release: 28 Feb 2012. Available from: URL: http://www.fda.gov

FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. Internet Document: 6 Mar 2012. Available from: URL: http://www.fda.gov

American Diabetes Association.American Diabetes Association Statement on Recent FDA Safety Changes in Labeling for Some Cholesterol-Lowering Drugs. Media Release: 29 Feb 2012. Available from: URL: http://www.diabetes.org

TGA - Therapeutic Goods Administration.Statins. Internet Document: 2 Mar 2012. Available from: URL: http://www.tga.gov.au

Title: Safety labelling changes for statins
Publication date: 01-03-2012
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2012
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201213920-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Safety labelling changes for statins

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Betamethasone

Sirolimus

Terbinafine

Methoxsalen

Adalimumab

Sodium phosphate overdose